Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020.
作者信息
Ajjawi Ismail, Loeb Stacy, Cooperberg Matthew R, Catalona William J, Gross Cary P, Ma Xiaomei, Leapman Michael S
机构信息
Yale School of Medicine, New Haven, Connecticut.
Department of Urology, New York University Langone Health, New York.
出版信息
JAMA. 2024 Dec 17;332(23):2033-2036. doi: 10.1001/jama.2024.20580.
Abstract
摘要
相似文献
1
Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020.
JAMA. 2024 Dec 17;332(23):2033-2036. doi: 10.1001/jama.2024.20580.
2
Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
J Urol. 2013 Nov;190(5):1742-9. doi: 10.1016/j.juro.2013.05.054. Epub 2013 May 30.
3
More Judicious Use of Expectant Management for Localized Prostate Cancer during the Last 2 Decades.
J Urol. 2017 Mar;197(3 Pt 1):614-620. doi: 10.1016/j.juro.2016.10.067. Epub 2016 Oct 27.
4
Racial Disparities in Active Surveillance for Prostate Cancer.
J Urol. 2017 Feb;197(2):342-349. doi: 10.1016/j.juro.2016.08.104. Epub 2016 Sep 3.
5
Active Surveillance for Men with Intermediate Risk Prostate Cancer.
J Urol. 2021 Jan;205(1):115-121. doi: 10.1097/JU.0000000000001241. Epub 2020 Jul 13.
6
Population-Based Assessment of Determining Treatments for Prostate Cancer.
JAMA Oncol. 2015 Apr;1(1):60-7. doi: 10.1001/jamaoncol.2014.192.
7
Trends in Active Surveillance for Men With Intermediate-Risk Prostate Cancer.
JAMA Netw Open. 2024 Aug 1;7(8):e2429760. doi: 10.1001/jamanetworkopen.2024.29760.
8
The experience of adults who choose watchful waiting or active surveillance as an approach to medical treatment: a qualitative systematic review.
JBI Database System Rev Implement Rep. 2016 Feb;14(2):174-255. doi: 10.11124/jbisrir-2016-2270.
9
Population-based assessment of determining predictors for quality of prostate cancer surveillance.
Cancer. 2015 Dec 1;121(23):4150-7. doi: 10.1002/cncr.29574. Epub 2015 Aug 26.
10
The Use and Short-term Outcomes of Active Surveillance in Men With National Comprehensive Cancer Network Favorable Intermediate-risk Prostate Cancer: The Initial Michigan Urological Surgery Improvement Collaborative Experience.
J Urol. 2023 Jan;209(1):170-179. doi: 10.1097/JU.0000000000003012. Epub 2022 Oct 13.
引用本文的文献
1
Five years later: no short answers for Long COVID.
Geroscience. 2025 Aug 28. doi: 10.1007/s11357-025-01870-9.
2
Identifying cribriform and intraductal histology on magnetic resonance imaging-assisted biopsy for patients with intermediate-grade prostate cancer: Implications for active surveillance.
Cancer. 2025 Jul 15;131(14):e35968. doi: 10.1002/cncr.35968.
3
Is uptake of AS in low-risk prostate cancer in Ontario linked to guideline publication?
Can Urol Assoc J. 2025 Jun;19(6):165-166. doi: 10.5489/cuaj.9282.
4
Trends in Surgical Overtreatment of Prostate Cancer.
JAMA Oncol. 2025 Apr 28. doi: 10.1001/jamaoncol.2025.0963.
5
Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment.
BJU Int. 2025 Aug;136(2):245-253. doi: 10.1111/bju.16727. Epub 2025 Apr 14.
本文引用的文献
1
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.
JAMA. 2024 Jun 25;331(24):2084-2093. doi: 10.1001/jama.2024.6695.
2
NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024.
J Natl Compr Canc Netw. 2024 Apr;22(3):140-150. doi: 10.6004/jnccn.2024.0019.
3
Use of Active Surveillance vs Definitive Treatment Among Men With Low- and Favorable Intermediate-Risk Prostate Cancer in the US Between 2010 and 2018.
JAMA Intern Med. 2023 Jun 1;183(6):608-611. doi: 10.1001/jamainternmed.2022.7100.
4
Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation.
J Urol. 2023 Apr;209(4):710-718. doi: 10.1097/JU.0000000000003159. Epub 2023 Feb 8.
5
Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and Metaregression.
Eur Urol Oncol. 2022 Dec;5(6):617-627. doi: 10.1016/j.euo.2022.07.004. Epub 2022 Aug 4.
6
Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance.
J Natl Compr Canc Netw. 2022 Feb;20(2):151-159. doi: 10.6004/jnccn.2021.7065.
Zotero 插件